Intervention Effect of High Definition Transcranial Alternating Current Stimulation (HD-tACS) on Depressive Disorder
1 other identifier
interventional
60
1 country
1
Brief Summary
To investigate the intervention effect of high definition transcranial alternating current stimulation (HD-tACS) on suicidal ideation in patients with depressive disorder and its underlying neural mechanism by magnetic resonance imaging (MRI) and electroencephalography (EEG).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2022
CompletedFirst Submitted
Initial submission to the registry
May 11, 2023
CompletedFirst Posted
Study publicly available on registry
July 6, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 20, 2025
CompletedJanuary 21, 2026
June 1, 2023
2.5 years
May 11, 2023
January 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Beck Scale for Suicide Ideation (BSS) Score
The BSS is a 19-item scale to measure the severity of suicidal ideation, where each item is rated on a scale from 0 to 2. The BSS total score ranges from 0 to 38 with lower scores indicating less suicidal ideation.
baseline, week 1 (end of treatment), and week 5 (end of follow-up)
Secondary Outcomes (9)
Beck Scale for Suicide Ideation (BSS) Response Rate (≥50% Improvement From Baseline)
week 1 (end of treatment) and week 5 (end of follow-up)
Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
baseline, week 1 (end of treatment), and week 5 (end of follow-up)
Change in Hamilton Depression Rating Scale (HAMD) Score
baseline, week 1 (end of treatment), and week 5 (end of follow-up)
Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score
baseline, week 1 (end of treatment), and week 5 (end of follow-up)
Change in Beck Depression Inventory (BDI) Score
baseline, week 1 (end of treatment), and week 5 (end of follow-up)
- +4 more secondary outcomes
Study Arms (2)
real stimulation
ACTIVE COMPARATORThe central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 30 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.
sham stimulation
SHAM COMPARATORIn the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 30-minute intervention. Participants will receive sham tACS twice daily for two weeks.
Interventions
tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
Eligibility Criteria
You may qualify if:
- the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for depression, and item 3 of the HAMD≥3.
- the age ranged from 18 to 65 years old, and the length of education was more than 5 years.
- the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests.
You may not qualify if:
- accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on.
- accompanied by other neurological diseases, such as stroke, epilepsy and so on. pregnant and lactating women.
- accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Yanghua Tian
Hefei, Anhui, 230022, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yanghua Tian, PhD
Anhui Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of medical psychological department, Anhui Medical University
Study Record Dates
First Submitted
May 11, 2023
First Posted
July 6, 2023
Study Start
September 1, 2022
Primary Completion
February 20, 2025
Study Completion
February 20, 2025
Last Updated
January 21, 2026
Record last verified: 2023-06